Open AccessAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Author(s) -
Gregory G. Schwartz,
Philippe Gabríel Steg,
Michael Szarek,
Deepak L. Bhatt,
Vera Bittner,
Rafael Díaz,
Jay M. Edelberg,
Shaun G. Goodman,
Corinne Hanotin,
Robert A. Harrington,
J. Wouter Jukema,
Guillaume Lecorps,
Kenneth W. Mahaffey,
Angèle Moryusef,
Robert Pordy,
Kirby Quintero,
Matthew T. Roe,
William J. Sasiela,
JeanFrançois Tamby,
Pierluigi Tricoci,
Harvey D. White,
Andreas M. Zeiher
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1801174
Subject(s) - alirocumab , acute coronary syndrome , medicine , cardiology , myocardial infarction , cholesterol , apolipoprotein a1 , apolipoprotein b
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom